190
Participants
Start Date
May 13, 2015
Primary Completion Date
December 22, 2017
Study Completion Date
December 22, 2017
CM-AT
Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
PLACEBO
Single unit dose powder of non-active substance administered 3 times per day for 90 days
Richmond Behavioral Associates, Staten Island
Montefiore Med.Center, Autism & Obsessive Compulsive Spectrum Prog., The Bronx
Neuroscience, Inc., Herndon
University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville
Carilion Clinic-Virginia Tech, Carilion School of Medicine, Roanoke
Duke Center For Autism and Brain Development, Durham
Carolina Clinical Trials, Inc., Charleston
Florida Hospital Medical Group-Lake Mary Pediatrics, Orange City
Kaley Kildahl, Orlando
Segal Institute For Clinical Research, North Miami
Cleveland Clinic, Center For Autism Research, Cleveland
Research Institute of Deaconess Clinic, Evansville
Detroit Clinical Research Center, P.C., Bingham Farms
Lake Charles Clinical Trials, Lake Charles
L.S.U. Health Sciences Center, Shreveport
Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.), Little Rock
University of Texas, Houston Dept. of Psychiatry and Behavioral Sciences, Houston
IMMUNOe RESEARCH CENTERS, Centennial
Ericksen Research & Development, Clinton
Southwest Autism Research & Resource Center (S.A.R.R.C.), Phoenix
University of Arizona, Pediatrics Multidisciplinary Research Unit, Tucson
Lovelace Scientific Resources, Albuquerque
N.R.C. Research Institute, Orange
M.I.N.D. Institute (Univ.of California, Davis), Sacramento
University of California (U.C.S.F.), San Francisco
Yale Child Study Center, New Haven
Children'S Specialized Hospital, Egg Harbor
Children'S Specialized Hospital, Toms River
Clinical Research Center of Nj, Voorhees Township
Omega Medical Research, Warwick
Vanderbilt University Med.Center -Treatment & Research Inst. For Asd, Nashville
Lead Sponsor
Curemark
INDUSTRY